Hypertonic Saline Therapy in Cystic Fibrosis: Do Population Shifts Caused by the Osmotic Sensitivity of Infecting Bacteria Explain the Effectiveness of this Treatment?
暂无分享,去创建一个
B. Ryall | J. Bundy | H. Williams | V. Behrends | J. Zlosnik
[1] Thomas Bjarnsholt,et al. Antibiotic resistance of bacterial biofilms. , 2010, International journal of antimicrobial agents.
[2] S. Anderson,et al. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. , 2010, Chest.
[3] T. Tolker-Nielsen,et al. Interference of Pseudomonas aeruginosa signalling and biofilm formation for infection control , 2010, Expert Reviews in Molecular Medicine.
[4] B. Ryall,et al. Metabolic profiling of Pseudomonas aeruginosa demonstrates that the anti-sigma factor MucA modulates osmotic stress tolerance. , 2010, Molecular bioSystems.
[5] D. Hassett,et al. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies , 2010, Expert opinion on therapeutic targets.
[6] G. Pier,et al. Evaluation of Flagella and Flagellin of Pseudomonas aeruginosa as Vaccines , 2009, Infection and Immunity.
[7] H Omran,et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children , 2009, European Respiratory Journal.
[8] L. Touqui,et al. Pseudomonas aeruginosa LPS or Flagellin Are Sufficient to Activate TLR-Dependent Signaling in Murine Alveolar Macrophages and Airway Epithelial Cells , 2009, PloS one.
[9] H. D. Liggitt,et al. Role of Toll-like receptor 5 in the innate immune response to acute P. aeruginosa pneumonia. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[10] N. Høiby,et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients , 2009, Pediatric pulmonology.
[11] J. Davies,et al. Bugs, biofilms, and resistance in cystic fibrosis. , 2009, Respiratory care.
[12] V. McDonald,et al. Nebulised hypertonic saline for cystic fibrosis. , 2009, The Cochrane database of systematic reviews.
[13] Joseph O Matu,et al. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. , 2009, Trends in microbiology.
[14] J. Bundy,et al. Time-Resolved Metabolic Footprinting for Nonlinear Modeling of Bacterial Substrate Utilization , 2009, Applied and Environmental Microbiology.
[15] J. Foweraker. Recent advances in the microbiology of respiratory tract infection in cystic fibrosis , 2008, British medical bulletin.
[16] Colin Wallis,et al. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis , 2008, Pediatric pulmonology.
[17] M. Surette,et al. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients , 2008, Proceedings of the National Academy of Sciences.
[18] Bruce A. Stanton,et al. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. , 2008, Pulmonary pharmacology & therapeutics.
[19] T. C. Briles,et al. Inhibitory effects of hypertonic saline on P. aeruginosa motility. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[20] S. Anderson,et al. Inhaled mannitol improves lung function in cystic fibrosis. , 2008, Chest.
[21] M. Wolfgang,et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. , 2008, American journal of respiratory and critical care medicine.
[22] M. Gadjeva,et al. Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. , 2008, Trends in molecular medicine.
[23] S. M. Kirov,et al. Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. , 2007, Microbiology.
[24] R. Boucher. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. , 2007, Trends in molecular medicine.
[25] Alan R. Brown,et al. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. , 2007, Future microbiology.
[26] M. Stanton,et al. Cystic fibrosis mortality and survival in the UK: 1947–2003 , 2007, European Respiratory Journal.
[27] T. Murray,et al. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients , 2007, Current opinion in pediatrics.
[28] C. Goss,et al. Exacerbations in cystic fibrosis · 1: Epidemiology and pathogenesis , 2007, Thorax.
[29] S. Randell,et al. Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance , 2007, Toxicologic pathology.
[30] S. M. Kirov,et al. Biofilm dispersal and exacerbations of cystic fibrosis lung disease , 2006, Pediatric pulmonology.
[31] F. Ratjen. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis , 2006, Current opinion in pulmonary medicine.
[32] A. J. Leech,et al. Cell wall‐inhibitory antibiotics activate the alginate biosynthesis operon in Pseudomonas aeruginosa: roles of σ22 (AlgT) and the AlgW and Prc proteases , 2006, Molecular microbiology.
[33] A. Verkman,et al. Hypertonic Saline Therapy in Cystic Fibrosis , 2006, Journal of Biological Chemistry.
[34] M. Whiteley,et al. Microarray Analysis of the Osmotic Stress Response in Pseudomonas aeruginosa , 2006, Journal of bacteriology.
[35] Mark R Elkins,et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. , 2006, The New England journal of medicine.
[36] M. Knowles,et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. , 2006, The New England journal of medicine.
[37] J. Davies. Current and Novel Antimicrobial Approaches , 2005 .
[38] D. Hassett,et al. Pseudomonas aeruginosa Biofilm Infections in Cystic Fibrosis , 2005 .
[39] D. VanDevanter,et al. How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis? , 2005, Pediatric pulmonology.
[40] D. Wozniak,et al. Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis , 2005, Molecular microbiology.
[41] A. Chakrabarty,et al. The algT ( algU ) gene of Pseudomonas aeruginosa , a key regulator involved in alginate biosynthesis , encodes an alternative a-factor (-E ) ( cystic fibrosis / virulence / in vitro transcription ) , 2005 .
[42] H. Baker,et al. MucA-Mediated Coordination of Type III Secretion and Alginate Synthesis in Pseudomonas aeruginosa , 2004, Journal of bacteriology.
[43] D. Hassett,et al. The Transcriptional Regulator AlgR Controls Cyanide Production in Pseudomonas aeruginosa , 2004, Journal of bacteriology.
[44] M. Hazucha,et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. , 2004, American journal of respiratory and critical care medicine.
[45] R. Gibson,et al. Pathophysiology and management of pulmonary infections in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.
[46] V. Deretic,et al. Microarray Analysis of Global Gene Expression in Mucoid Pseudomonas aeruginosa , 2003, Journal of bacteriology.
[47] Gerald B. Pier,et al. Lung Infections Associated with Cystic Fibrosis , 2002, Clinical Microbiology Reviews.
[48] V. Deretic,et al. Global Genomic Analysis of AlgU (σE)-Dependent Promoters (Sigmulon) in Pseudomonas aeruginosa and Implications for Inflammatory Processes in Cystic Fibrosis , 2002, Journal of bacteriology.
[49] S. Molin,et al. Alginate Overproduction Affects Pseudomonas aeruginosa Biofilm Structure and Function , 2001, Journal of bacteriology.
[50] F. Ratjen. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. , 2001, International journal of antimicrobial agents.
[51] M. Hodson,et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. , 2000, The European respiratory journal.
[52] V. Deretic,et al. Membrane‐to‐cytosol redistribution of ECF sigma factor AlgU and conversion to mucoidy in Pseudomonas aeruginosa isolates from cystic fibrosis patients , 2000, Molecular microbiology.
[53] S. Anderson,et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. , 1999, The European respiratory journal.
[54] S. Molin,et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. , 1999, Microbiology.
[55] S. Randell,et al. Evidence for Periciliary Liquid Layer Depletion, Not Abnormal Ion Composition, in the Pathogenesis of Cystic Fibrosis Airways Disease , 1998, Cell.
[56] M. King,et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. , 1997, Thorax.
[57] V. Deretic,et al. Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection , 1997, Infection and immunity.
[58] M. King,et al. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. , 1997, American journal of respiratory and critical care medicine.
[59] J. Mattick,et al. The alginate regulator AlgR and an associated sensor FimS are required for twitching motility in Pseudomonas aeruginosa. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[60] V. Deretic,et al. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. , 1996, Microbiological reviews.
[61] V. Deretic,et al. Control of AlgU, a member of the sigma E-like family of stress sigma factors, by the negative regulators MucA and MucB and Pseudomonas aeruginosa conversion to mucoidy in cystic fibrosis , 1996, Journal of bacteriology.
[62] M. King,et al. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. , 1996, American journal of respiratory and critical care medicine.
[63] A. Chakrabarty,et al. The algT (algU) gene of Pseudomonas aeruginosa, a key regulator involved in alginate biosynthesis, encodes an alternative sigma factor (sigma E). , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[64] D. Martin,et al. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[65] F. Collins,et al. Cystic fibrosis: molecular biology and therapeutic implications. , 1992, Science.
[66] S. Schwarzmann,et al. Antiphagocytic Effect of Slime from a Mucoid Strain of Pseudomonas aeruginosa , 1971, Infection and immunity.
[67] J. Gustafson,et al. Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.